| Document |
Document Title |
|
WO/2021/079435A1 |
This composition is for lysing Staphylococcus aureus or treating or preventing diseases caused by Staphylococcus aureus, and contains, as active ingredients, at least one bacteriophage selected from the group consisting of the bacterioph...
|
|
WO/2021/077994A1 |
Disclosed are a new crystal form of compound I and a preparation method therefor, a pharmaceutical composition comprising the crystal form, and the use of the crystal form in the preparation of hypoxia-inducible factor-prolyl hydroxylase...
|
|
WO/2021/079984A1 |
The present invention provides a novel compound having an excellent β-lactamase inhibitory effect. The present invention provides: a compound which has an excellent β-lactamase inhibitory effect, and is represented by formula (1a), (1b...
|
|
WO/2021/078077A1 |
Disclosed are a new crystal form of acetylated eltrombopag and a preparation method therefor, belonging to the field of pharmaceutical chemistry. The crystal form has better stability, which is conducive to storage, transfer, and operati...
|
|
WO/2021/077034A1 |
Disclosed herein are methods of treating or suppressing a disorder selected from the group consisting of hemoglobinopathy, thalassemia, α-thalassemia, α-thalassemia minima, α-thalassemia minor, β-thalassemia, β-thalassemia minor, β...
|
|
WO/2021/075568A1 |
The present invention provides a method for producing a megakaryocyte progenitor cell or a megakaryocytic cell, the method comprising a step of suppressing the expression of CDKN1A gene or the function of an expression product of the gen...
|
|
WO/2021/076709A1 |
Embodiments of the present disclosure relate to doses of ornithine phenylacetate for treating or ameliorating hyperammonemia and the methods of administrating the same in a patient with a chronic liver disease, for example, cirrhosis. In...
|
|
WO/2021/076991A1 |
The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating a blood disorder ( e.g., cold agglutinin hemolytic anemia (cold agglutinin disease), cold antibody hemolytic anemia, ABO incompat...
|
|
WO/2021/076514A1 |
Methods for treating immune thrombocytopenia comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-
d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxeta
n-3-yl)pipe...
|
|
WO/2021/076485A1 |
Disclosed herein are methods of reducing, preventing, or ameliorating tissue iron overload and disorders associated with depletion/reduction of plasm haptoglobin levels in the presence of increased plasma hemoglobin levels due to hemolys...
|
|
WO/2021/073038A1 |
Disclosed in present invention are an o-hydroxybenzoic acid polyglycol ester compound, and a synthetic preparation method and pharmaceutical use thereof. The o-hydroxybenzoic acid polyglycol ester compound has a structure shown as formul...
|
|
WO/2021/073610A1 |
Provided are methods and compositions for treating diseases or disorders related to hematopoietic dysfunctions and/or injuries, or for rejuvenating HSPCs.
|
|
WO/2021/071751A1 |
The present embodiments provide systems and medical formulations suitable for delivering therapeutic powders to a target site. In one embodiment, the system comprises a delivery device, a first powder being formed of particles of a first...
|
|
WO/2021/068239A1 |
Disclosed are a vaginal slow-release administration system for luteal support, a preparation method therefor and a use thereof. The system is a progesterone reservoir type vaginal ring, comprising a core layer, and a film layer double-la...
|
|
WO/2021/072194A1 |
The present disclosure provides stabilized hemoglobin compositions, uses thereof, and devices for administration thereof. The stabilized hemoglobin compositions may be useful in the treatment of various anemic or traumatic conditions inv...
|
|
WO/2021/070885A1 |
The present inventors have found that acquired hemophilia A can be prevented and/or treated effectively by administering a pharmaceutical composition containing emicizumab in accordance with a specific dosing regimen.
|
|
WO/2021/067914A1 |
The present disclosure provides for methods and compositions for preventing and treating myelodysplastic syndromes, acute myeloid leukemia, and other diseases and disorders of the blood, using a combination therapy including all-trans re...
|
|
WO/2021/066578A1 |
The present invention relates to a compound derivative bearing a 6-7 bicyclic ring and a use thereof. The compound according to the present invention acts as a protein arginine methyltransferases 5 (PRMT5) inhibitor and thus can be advan...
|
|
WO/2021/064151A1 |
The present invention relates to the use of eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester, optionally in combination with vitamin D3, in prevention of decline in lean muscle mass, falls with and without an injury...
|
|
WO/2021/067389A1 |
Lentiviral vector (LV) formulations, and pharmaceutical compositions comprising such LV formulations, with improved stability and suitable for systemic administration are provided. Methods for treating disorders, especially blood disorde...
|
|
WO/2021/065768A1 |
Provided is a preparation which is co-administered with a protein preparation and can increase the administration volume of the protein preparation even when administered at a low concentration. This space-forming agent forms, under the ...
|
|
WO/2021/066152A1 |
The purpose of the present invention is to provide a blood treatment material which can adsorb and remove blood components including activated leukocytes and inflammatory cytokines with high efficiency. The present invention provides a b...
|
|
WO/2021/067668A1 |
The disclosure provides a method for treating and/or preventing graft rejection with A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13). The disclosure provides a method for increasing ADAMTS13-med...
|
|
WO/2021/066649A1 |
The invention provides method of treatment comprising administering an AQGV peptide, or a functional analogue thereof, to a human subject, the human subject optionally having impaired kidney function, wherein the treatment of administeri...
|
|
WO/2021/058117A1 |
The present invention relates to methods of treating or preventing hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) in a subject, which comprises administering to the subject a therapeutically or prophy...
|
|
WO/2021/058835A1 |
The present disclosure relates to acidic sophorolipids and uses thereof, including for use in therapy and, in particular, in the treatment or prevention of cancer and associated pathologies.
|
|
WO/2021/062012A1 |
Methods are disclosed herein for treating atherosclerosis and/or decreasing arterial endothelial inflammation in a subject. These methods include administering to the subject a therapeutically effective amount of a Kallikrein Related Pep...
|
|
WO/2021/057082A1 |
The present invention relates to the technical field of biological medicines, and in particular, to a pyridine sulfonamide phosphate compound, a preparation method therefor and application thereof. The present invention has the beneficia...
|
|
WO/2021/062238A1 |
This disclosure relates to methods and compositions for treating sickle cell anemia or thalassemia in a subject in need thereof. As described herein in a first aspect the present disclosure provides a method of treating an inherited bloo...
|
|
WO/2021/057680A1 |
Disclosed is an application of 2,4-dihydroxybenzoic acid or an isomer thereof in foods, health products or medicines for treating or preventing related diseases or conditions caused by iron overload. The isomer of the 2,4-dihydroxybenzoi...
|
|
WO/2021/057818A1 |
Provided in the present invention is a series of selective Factor XIa (FXIa) inhibitors, relating to the technical field of chemical drugs. The present invention also relates to pharmaceutical compositions containing said compounds and a...
|
|
WO/2021/060303A1 |
[Problem] To provide fluorocarbon-based core-shell microparticles that can be used as artificial oxygen carriers. [Solution] Core-shell microparticles each containing: a shell that includes a polymer having a Young's modulus of 100 MPa o...
|
|
WO/2021/056609A1 |
Disclosed are a sequence of a polypeptide antigen, the spatially sensitive position of the polypeptide antigen in human von Willebrand factor and the use of the polypeptide antigen in the preparation of a preparation for diagnosing and/o...
|
|
WO/2021/051807A1 |
Disclosed is a method for preparing a preparation of human albumin, the method comprising controlling the content of a long chain fatty acid in the preparation; and adding a poloxamer. The long chain fatty acid is selected from one or mo...
|
|
WO/2021/052470A1 |
Provided are an RNA activation mechanism-based small activating nucleic acid molecule and application thereof in treatment of THPO protein deficiency or insufficiency-related diseases or symptoms such as immune thrombocytopenia. The smal...
|
|
WO/2021/055863A1 |
The present disclosure provides crystalline solid forms, spray-dried dispersions and pharmaceutical compositions, including solid oral dosage forms, of (S)-1-(5-[2H,3H-[1,4]dioxino[2,3-b]pyridine-7-sulfonyl]-1H,2
H,3H,4H,5H,6H-pyrrolo[3,...
|
|
WO/2021/053518A1 |
A method of producing a bioextract from a snake fish comprising steps of selecting of a snake fish, cleaning the snake fish, reducing the snake fish down to manageable pieces by cutting, milling the snake fish, utilizing an extracting pr...
|
|
WO/2021/054473A1 |
The present invention provides: an agent that is for ameliorating and/or preventing sickle cell disease and that contains 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt thereof; and amelioration and/or prevention of sickl...
|
|
WO/2021/055807A1 |
The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfo
nyl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrroll-2(1H)-yl)-3-hydroxy-2-phenyl
propan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the a...
|
|
WO/2021/051262A1 |
A traditional Chinese medicine composition and an application thereof. The traditional Chinese medicine composition is prepared from Fructus Aurantii Immaturus, Rhizoma Atractylodis Macrocephalae, Radix Ginseng, Fructus Lycii, Colla Cori...
|
|
WO/2021/049978A1 |
The invention relates to the pharmaceutical industry, namely to a hemostatic composition with reparative properties (variants). The hemostatic composition with reparative properties in the form of a gel containing xymedone, modified chit...
|
|
WO/2021/049504A1 |
The present invention provides: a conjugate of an oligonucleotide having a nucleotide sequence that is expected to have a pharmacological effect in a hepatic parenchymal cell and a biantennary GalNAc unit, or a pharmaceutically acceptabl...
|
|
WO/2021/049612A1 |
The present invention pertains to a drug for improving fluid retention in acute heart failure, the drug containing an SGLT2 inhibitor.
|
|
WO/2021/050568A1 |
Compositions containing populations of nanoparticles that show selective uptake by tissues and other cell types such as lung cells and/or bone marrow cells are described. The nanoparticles show this uptake by virtue of their size and in ...
|
|
WO/2021/049617A1 |
Disclosed are: a composition of a serum-free medium not containing albumin and suited for culturing human hematopoietic stem cells; and an albumin-free culturing method. The present invention provides a method for culturing human hematop...
|
|
WO/2021/047555A1 |
Provided are the preparation of an aromatic heterocyclic derivative as an immunomodulator and an application thereof. Specifically, provided is a compound represented by formula I below, or an optical isomer, hydrate, solvate, or pharmac...
|
|
WO/2021/045184A1 |
The present invention addresses the problem of providing a therapeutic agent for polycythemia. According to the present invention, provided is a therapeutic agent for polycythemia, the inhibitor comprising antibodies that recognize the 6...
|
|
WO/2021/045554A1 |
The present invention relates to a pharmaceutical composition for preventing or treating at least one disease selected from hyperlipidemia, dyslipidemia, hypercholesterolemia, hypertriglyceridemia, hypertension, arteriosclerosis, coronar...
|
|
WO/2021/043127A1 |
Disclosed is a new chimeric protein, comprising a first polypeptide chain and a second polypeptide chain. The first polypeptide chain comprises a coagulation factor and a first Fc variant of an Fc domain of an immunoglobulin, and the sec...
|
|
WO/2021/046500A1 |
Disclosed herein are lentiviral vector transduction efficiency assays for gene therapy treatments. Also disclosed herein are methods for measuring transduction efficiency of a lentiviral vector. A single cell PCR (scPCR) assay has been d...
|
